

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 October 2020 (15.10.2020)



(10) International Publication Number
WO 2020/210684 A1

(51) International Patent Classification:

A61K 31/508 (2006.01) A61P 25/16 (2006.01)
C07D 403/12 (2006.01)

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2020/027742

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

10 April 2020 (10.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/832,775 11 April 2019 (11.04.2019) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, California
94080 (US).

(72) Inventors: **DE VICENTE FIDALGO, Javier**; c/o Denali
Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco,
California 94080 (US). **ESTRADA, Anthony A.**; c/o
Denali Therapeutics Inc., 161 Oyster Point Blvd., South San
Francisco, California 94080 (US). **FENG, Jianwen A.**; c/o
Denali Therapeutics Inc., 161 Oyster Point Blvd., South San
Francisco, California 94080 (US). **SWEENEY, Zachary
K.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd.,
South San Francisco, California 94080 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN
RICHTER & HAMPTON LLP, 650 Town Center Drive,
10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS

(57) Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.

WO 2020/210684 A1